Novo in supply deal with Ypsomed for auto-injector pens
Novo Nordisk A/S, which faces higher demand for its diabetes and weight-loss drugs than it can meet, signed a long-term agreement with Ypsomed Holding AG for the supply of auto-injectors.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Reuters: Novo Nordisk expands Catalent supply agreement
For subscribers